ArticleThe oncologist2025
Survivorship in advanced ovarian cancer: a prognostic model for overall survival and risk of recurrence.
Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Predictive factors for long-term survivors in advanced-stage epithelial ovarian cancer.AJOG global reports · 2026Article
- Prognostic Factors of Advanced Ovarian Cancer in the Era of HIPEC: A Multicenter Retrospective Study from an ESGO-Certified Center and an ESPSO-Certified Center.Biomedicines · 2026Article
- Shifting Survival Horizons in Advanced Ovarian Cancer: A Conditional Survival Perspective.Current oncology (Toronto, Ont.) · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
Abstract
objectiveAdvanced epithelial ovarian cancer (EOC) poses a significant clinical challenge due to its typically late diagnosis and poor prognosis. However, a subset of patients exhibit remarkably prolonged survival. Identifying prognostic factors and developing tools for estimating outcomes may provide tailored strategies for treatment escalation or de-escalation. This study aimed to identify prognostic factors associated with patient survival and develop a prognostic model estimating EOC patients' overall survival and risk of recurrence (ROR).
methodsWe conducted a retrospective analysis of 1049 women diagnosed with EOC from January 2002 until June 2024. Clinical, pathological, and molecular data, including germline BRCA pathogenic variants (PVs), and homologous recombination repair analysis were performed. Long-term survivors (LTS), defined as those surviving over 7 or 10 years, and short-term survivors (STS), defined as those surviving less than 2 years were compared. A prognostic model was developed using multivariable logistic regression to estimate survival probabilities and recurrence risk.
resultsAmong the study cohort with advanced disease (FIGO stage III-IV), 20.3% survived beyond 7 years and 9.8% beyond 10 years. Factors significantly associated with LTS included younger age, lower disease stage, complete tumor resection, BRCA PV, and treatment with poly (ADP-ribose) polymerase inhibitors. The prognostic model, integrating age, stage, BRCA status, and tumor resection, provided survival estimates and ROR for 2, 5, 7, and 10 years from diagnosis. This tool is based on retrospective logistic regression analysis of long-term and STS across all stages (I-IV).
conclusionsThis study reaffirms established prognostic factors of LTS with advanced EOC and introduces a novel prognostic calculator integrating clinical variables. The tool may assist in personalizing treatment plans and guiding clinical decisions. Validation in multi-institutional cohorts is necessary to confirm its universal utility and applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.